Home › Osteosarcoma › Massachusetts
Osteosarcoma clinical trials in Massachusetts
9 studies for Osteosarcoma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 29, 2026 · NCT04616560Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Up to age 50 · All sexes · Updated Aug 25, 2026 · NCT05235165SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Aug 3, 2026 · NCT06239272Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 1, 2026 · NCT07357519Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Apr 17, 2026 · NCT05019703Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
RecruitingPhase 1/2
Ages 12 to 49 · All sexes · Updated Feb 19, 2026 · NCT06709495From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.